



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

April 11, 2012

Via Email
Qingtai Liu
Chief Executive Officer
Shengtai Pharmaceutical, Inc.
Changda Road East, Development District, Changle
County, Shandong, People's Republic of China 262400

Re: Shengtai Pharmaceutical, Inc.
Form 10-K for the fiscal year ended June 30, 2011
Filed October 7, 2011
File No. 000-51312

Dear Mr. Liu:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler
Assistant Director

cc: Benjamin Tan (Sichenzia Ross Friedman Ference LLP)